Heart Attack Breakthrough
Heart
Attack Breakthrough
A myocardial infarction, or otherwise known as a heart attack, occurs
when the supply of blood to the heart is blocked, the main cause of this
usually being blood clots. Coronary heart disease is the prominent cause of
heart attacks each year, with approximately 73,000 losing their lives due to
the disease. Heart and circulatory diseases are life threatening, but research
from US scientists regarding unchecked inflammation has uncovered new information which is being hailed as the ‘biggest
breakthrough since statins’.
Individuals who had suffered from a heart attack were injected with an
anti-inflammatory drug known as
canakinumab, and follow up research found that not only did they experience fewer
heart attacks in the future but also the risk of cancer was reduced by 50%.
Why was there a need for further research into heart diseases?
Statins are currently integral to
the treatment of people who have heart diseases. Statins are a group of
medicines with the function of lowering the level of low-density lipoprotein
(LDL) cholesterol present in the blood. LDL cholesterol is produced in the
liver, and becomes dangerous in large amounts as it is able to cause arteries
to harden and narrow, which in turn will reduce the amount of blood that is
able to be pumped through them, leading to one of a number of possible heart
diseases including angina, strokes as well as heart diseases. Thus, statins are
an integral part of treatment.
However, statistics show that one
quarter of people who have previsouly had heart attacks and take statins persistently will still have another one in
the next five years. The reason for this is believed to be unmonitored
inflammation of the arteries. Therefore, prescribing an anti-inflammatory drug such
as canakinumab alongside the statins may have combined effects. When
canakinumab was tested on 10,000 individuals who had previously had a heart
attack and had inflammation within the body, the possibility of another heart
attack happening was reduced by 15%. Not only this, but there was a further
reduction of 30% in regards to the number of intervention procedures that would
be needed which are very expensive, including bypass surgery.
Importantly, the team have been
able to add scientific weight to the relationship between inflammation and cardiovascular
health, to bring about a more specific and promising direction for treatment to
enhance the benefits of statins used today. However, it is unsurprising that
the discovery does not come without implications. There is an increased chance
of contracting a severe infection which may lead to death, an element which
must first be isolated and understood before inti-inflammatory drugs can take precedent.
Statins will still be the main form of medication at present, but the data
collected from the research is invaluable and has certainly established promise
for improved healthcare for those with heart diseases.
I hope you enjoyed the post this
week, thank you for reading!
By Vicale Czan Alfanti
Universal Medicine
Comments
Post a Comment